NEW YORK (GenomeWeb) – Australian biotech firm Reproductive Health Science said that it has signed a three-year exclusive agreement with Tani Medikal for the distribution of RHS's EmbryoCellect kit for pre-implantation genetic screening for in vitro fertilization.
Tani Medikal is based in Turkey and will distribute EmbryoCellect in Turkey, Azerbaijan, Georgia, Turkish Republic of Northern Cyprus, Kosovo, Macedonia, and North Iraq (Kurdish region).
EmbryoSelect uses microarray-based comparative genomic hybridization to compare the number of chromosomes in a sample cell to a known reference sample, providing a way to count the number of chromosomes in the test cell and detect whole chromosome aneuploidy.
Adelaide-based RHS went public in April after raising A$3 million (US$2.8 million at the time) and completing a reverse merger with AO Energy, a publicly traded mining company.